Production (Stage)
Anika Therapeutics, Inc.
ANIK
$11.24
-$0.53-4.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 137.44M | 140.30M | 106.80M | 109.51M | 111.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 137.44M | 140.30M | 106.80M | 109.51M | 111.89M |
| Cost of Revenue | 76.23M | 74.79M | 53.24M | 31.70M | 32.48M |
| Gross Profit | 61.22M | 65.51M | 53.55M | 77.81M | 79.41M |
| SG&A Expenses | 63.15M | 65.31M | 38.40M | 44.12M | 48.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 166.58M | 167.66M | 109.36M | 94.08M | 100.25M |
| Operating Income | -29.14M | -27.36M | -2.56M | 15.43M | 11.64M |
| Income Before Tax | -30.69M | -28.73M | -3.49M | 17.08M | 13.26M |
| Income Tax Expenses | 5.76M | 5.72M | 12.25M | 9.48M | 8.30M |
| Earnings from Continuing Operations | -36.45 | -34.45 | -15.73 | 7.61 | 4.96 |
| Earnings from Discontinued Operations | -20.29M | -21.94M | -2.56M | -2.56M | -2.56M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.74M | -56.39M | -97.52M | -74.18M | -76.83M |
| EBIT | -29.14M | -27.36M | -2.56M | 15.43M | 11.64M |
| EBITDA | -21.11M | -18.86M | 7.33M | 26.67M | 24.37M |
| EPS Basic | -3.87 | -3.84 | -6.64 | -5.06 | -5.24 |
| Normalized Basic EPS | -1.15 | -1.06 | -0.01 | 0.76 | 0.60 |
| EPS Diluted | -3.88 | -3.85 | -6.65 | -5.07 | -5.25 |
| Normalized Diluted EPS | -1.15 | -1.06 | -0.01 | 0.76 | 0.60 |
| Average Basic Shares Outstanding | 58.48M | 58.88M | 58.96M | 58.83M | 58.68M |
| Average Diluted Shares Outstanding | 58.53M | 58.93M | 58.96M | 58.83M | 58.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |